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Abstract
Background: In this study, we aimed to identify microRNA from urine of multiple myeloma patients that could
serve as a biomarker for the disease.
Results: Analysis of urine samples was performed using Serum/Plasma Focus PCR MicroRNA Panel (Exiqon) and
verified using individual TaqMan miRNA assays for qPCR. We found 20 deregulated microRNA (p < 0.05); for further
validation, we chose 8 of them. Nevertheless, only differences in expression levels of miR-22-3p remained close to
statistical significance.
Conclusions: Our preliminary results did not confirm urine microRNA as a potential biomarker for multiple
myeloma.
Background
Multiple myeloma (MM) is a malignancy of plasma cells
(PCs) that manifests also by renal insufficiency [1].
MicroRNAs (miRNAs) are small non-coding single
stranded RNAs and important regulators of gene expres-
sion involved in MM pathogenesis [2]. Currently, re-
search attention is focused on circulating miRNAs
which can be detected in various body fluids, also in
urine. Circulating miRNAs are highly stable and have
the potential to become easily available minimally inva-
sive biomarkers of the disease [3]. For MM, they would
represent a new more convenient approach since painful
and invasive bone marrow (BM) biopsy is used for dis-
ease diagnostics and monitoring. We hypothesized that
miRNAs identified in urine of MM patients could
become a completely non-invasive biomarker potentially
distinguishing MM patients from healthy donors (HD).
Results and discussion
Screening of miRNA in urine revealed 20 deregulated
miRNAs (p < 0.05 for all miRNAs) between MM and
HD (Fig. 1). For further validation, we chose 8 most
deregulated miRNAs between MM and HD: miR-200c-
3p, miR-29b-3p, miR-29c-3p, miR-22-3p, miR-29a-3p,
miR-25-3p, miR-106b-5p, miR-18a-3p (Table 1). Expres-
sion levels of these miRNAs were further verified on a
larger cohort of MM patients, RCC patients and HD.
Results from validation revealed that expression levels of
chosen miRNAs from urine of MM patients are not sta-
tistically different (p = 0.05) from HD and RCC patients
(Fig. 2). Results from validation did not confirm statis-
tical significance from the screening. Only differences in
expression levels of miR-22-3p between MM patients
and HD in urine (p = 0.090) remained close to statistical
significance (Table 2).
Nowadays, there is increasing evidence of miRNAs im-
portance in MM pathogenesis. MiRNA expression pro-
files could be useful for MM stratification, prognostic
estimation, prediction of therapeutic effectiveness or dis-
ease relapse [2, 4]. Moreover, miRNAs could potentially
provide deeper insight into molecular nature of the dis-
ease and help to develop miRNAs-based therapeutic
agents subsequently improving patients’ outcome [5]. It
has been shown that circulating miRNAs found in vari-
ous body fluids may serve as a new class of powerful
and minimally invasive biomarkers for MM. Although
several studies describing circulating miRNAs in periph-
eral blood of MM patients were published [6–8], no
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study focused on miRNA expression profiles in urine of
MM patients has been published so far.
As one of the typical clinical manifestations of MM is
renal insufficiency, included as one of the ‘CRAB’ criteria
for organ damage in MM [1], we hypothesized that miR-
NAs found in urine of MM patients could serve as diag-
nostic biomarkers of the disease. Twenty differentially
expressed miRNAs between MM and HD urine samples
were identified using Serum/Plasma Focus PCR Micro-
RNA Panel; out of them, eight miRNAs were chosen for
further analysis. Unfortunately, none of them was assessed
as significantly deregulated in a larger cohort of MM,
RCC patients and HD using individual TaqMan miRNA
assays. In our study, we included not only MM patients
and HD, but also RCC patients to exclude miRNA that
are related to kidney damage.
As no differences in miRNA expression were found in
the validation phase of the study, we considered several
reasons for this outcome. First reason is possible analyt-
ical difference between the screening and validation
phase of our study. We believe that using different
detection approaches (Serum/Plasma Focus PCR Micro-
RNA Panel versus individual TaqMan miRNA assays)
was not the reason for discordance between the screen-
ing and validation phase since they are both reliable
methods verified by many researchers [9, 10]. Second
reason is differences in sample collection and processing.
We believe that the discordance was not caused by dis-
unity of samples as they were all collected and processed
in the same manner. Third possibility is using cel-miR-
39 as a spike-in control for normalization. This approach
is now considered a suitable approach in relative quanti-
fication [11], and it was applied in both phases of the
study. On the other hand, a small cohort of patients
Fig. 1 Hierarchical clustering of differentially expressed miRNAs from urine between MM patients (yellow) and HD (blue) using heatmaps. Different
expression is expressed by range of red (overexpression) vs green (low expression) colors
Table 1 P values and sample size estimation for differentially
expressed miRNAs in the screening phase
miRNA P value adj.P value Sample size
hsa-miR-29b-3p 0.0043 0.2074 25.14
hsa-miR-29a-3p 0.0060 0.2074 81.74
hsa-miR-22-3p 0.0062 0.2074 58.68
hsa-miR-29c-3p 0.0111 0.2074 36.19
hsa-miR-25-3p 0.0176 0.2074 55.67
hsa-miR-106b-5p 0.0195 0.2074 32.32
hsa-miR-18a-3p 0.0303 0.2784 125.39
hsa-miR-200c-3p 0.0426 0.3121 29.50
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Fig. 2 Comparison of expression levels of validated miRNAs defined as logarithmic values of 2-ΔCt normalized to cel-miR-39 expression levels for
MM, RCC patients and HD. a – miR-29a-3p; b – miR-29b-3p; c – miR-29c-3p; d miR-25-3p; e – miR-22-3p; f – miR-106b-5p; g – miR-18a-3p;
h – miR-200c-3p
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used in the screening phase may be considered a major
limitation as it may not be powerful enough for identifi-
cation of a biomarker. Although the cohort seems to be
small, it is a standard way of identifying possible differ-
ences of miRNA expression [8, 10]. While it is possible
that we could have missed some significantly differently
expressed miRNAs, we found twenty miRNAs to be
deregulated (p < 0.05 for all miRNAs). In the design of
our study, the screening phase was not a test cohort, but
a way of finding significant miRNAs which should be
studied further; we believe that the screening phase
fulfilled this purpose.
Another possibility to be considered is the existence of
previously published work that identified urine miRNAs
as markers of various diseases – such work has been
done, for example in urologic cancers (reviewed in [12]).
Urinary miRNAs are easily accessible and quantifiable
and thus have a great potential to become biomarkers in
oncology and nephrology [12]. It has been previously
published that urinary miRNAs may be used for diagno-
sis and monitoring of urothelial carcinoma (UC).
Deregulated levels of miR-126, miR-96, miR-200 family
and miR-183 family were repeatedly observed in UC pa-
tients. Also, it was observed that increased expression
levels of urinary miR-15a could serve as a biomarker for
benign/malignant RCC differentiation [12].
Moreover, some of studied urinary miRNAs were
previously described in MM PCs [4, 13, 14]. Members
of the miR-29 family (miR-29a-3p, miR-29b-3p and
miR-29c-3p) were found in MM PCs with decreased
expression levels; also, presence of circulating miR-
29a was detected in serum of MM patients [13, 15].
Apart from hematological malignancies, increased ex-
pression levels of these miRNAs were found in RCC
Table 2 Validated microRNAs
miRNA HD MM RCC P value
mean mean mean









Std. deviation Std. deviation Std. deviation
miR-29a −1.007 −0.984 −0.833 0.863 0.466 0.739
(−1.145) - (−0.556) (−1.384) - (−0.715) (−1.172) - (−0.475)
0.559 0.506 0.393
miR-29b −2.204 −2.248 −2.064 0.570 0.394 0.581
(−2.458) - (−1.751) (−2.598) - (−1.848) (−2.352) - (−1.493)
0.446 0.580 0.438
miR-29c −1.386 −1.426 −1.252 0.663 0.329 0.565
(−1.656) - (−0.933) (−1.796) - (−1.040) (−1.570) - (−0.856)
0.482 0.518 0.361
miR-25 −2.224 −2.106 −2.347 0.692 0.329 0.608
(−2.593) - (−1.848) (−2.595) - (−1.717) (−2.742) - (−2.049)
0.598 0.634 0.567
miR-22 −2.532 −2.247 −2.310 0.090 0.790 0.225
(−2.954) - (−2.084) (−2.744) - (−1.782) (−2.566) - (−1.676)
0.538 0.689 0.536
miR-106b −1.788 −1.765 −1.612 0.958 0.496 0.776
(−2.120) - (−1.419) (−2.138) - (−1.423) (−1.901) - (−1.102)
0.460 0.555 0.524
miR-18a −2.736 −2.824 −3.416 0.763 0.528 0.802
(−4.359) - (0.000) (−4.171) - (0.000) (−4.303) - (−3.437)
2.101 1.874 1.563
miR-200c −0.909 −0.990 −0.645 0.543 0.088 0.237
(−1.273) - (−0.449) (−1.405) - (−0.588) (−0.963) - (−0.487)
0.610 0.595 0.374
Expression levels defined as logarithmic values of 2-ΔCt normalized to cel-miR-39 expression levels as mean value and interquantile range with standard deviation.
Nonparametric Kruskal-Wallis or Mann–Whitney U test was used to compare the values
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and decreased expression levels in diabetic nephropa-
thy (DN) [16].
Overexpression of cluster miR-106b-25 seems to be
contributing to transformation of monoclonal gammo-
pathy of undetermined significance (MGUS) patients to
MM as its expression levels are increased in both,
MGUS and MM PCs compared to HD [2]. Increased ex-
pression levels of miR-106b occur in RCC cells as well.
It was suggested that expression levels of this miRNA
could become a predictive biomarker for metastasis for-
mation after surgical removal of kidneys [14]. On the
other hand, miR-22 expression levels were found to be
decreased in MM cell lines and were associated with
17p deletion [4].
MiR-18a is member of the miR-17-92 cluster which is
present in PCs of MM patients with higher expression
levels. MiRNAs originating from this cluster of genes pro-
mote leukemogenesis. The miR-17-92 cluster is activated
by Myc and subsequently downregulates proapoptotic
protein Bim thus promoting MM cell proliferation and in-
hibition of cell apoptosis. Moreover, the miR-17-92 cluster
is linked to MM progression and poor prognosis [17]. On
contrary, decreased expression levels of miR-18a was de-
tected in bladder cancer [14, 18]. MiR-200c has not been
found in MM PCs so far. However, its decreased expres-
sion levels were shown in RCC and DN [19].
Conclusions
In conclusion, we have identified several miRNAs in
urine of MM patients that were previously described to
be involved in MM pathogenesis or kidney-associated
diseases but are not disease-specific. Thus, we could not
confirm our hypothesis that there is a set of circulating
urinary miRNA that could serve as a non-invasive
marker of MM.
Methods
In total, 85 urine samples were included in the study
(Table 3). Samples were collected as 8 mL of urine stabi-
lized by 0.149 g of EDTA. MiRNAs from 1 mL of urine
were isolated using Urine MicroRNA Purification Kit
(Norgen Biotek, Canada) according to manufacturer’s
recommendations and quantified using Nanodrop-
ND1000 spectrophotometer. 40 ng of isolated miRNA
was reverse transcribed by Universal cDNA Synthesis
Kit (Exiqon, Denmark). Analysis of potentially biologic-
ally significant miRNAs in urine was performed using
Serum/Plasma Focus PCR MicroRNA Panel (Exiqon,
Denmark) determining expression levels of 179 miRNAs
of 7 urine samples of newly diagnosed MM patients and
8 HD. Normalized expression data from the screening
phase of the study were statistically analyzed by freeware
R/Bioconductor and its additional packages. LIMMA ap-
proach was used to identify differentially expressed
miRNAs with Benjamini-Hochberg adjustment of P
values. To clarify similarity of samples, hierarchical clus-
tering was applied. Individual TaqMan miRNAs assays
for 8 differentially expressed miRNAs (hsa-miR-200c-3p,
hsa-miR-29b-3p, hsa-miR-29c-3p, hsa-miR-22-3p, hsa-
miR-29a-3p, hsa-miR-25-3p, hsa-miR-106b-5p, hsa-miR-
18a-3p, Life Technologies, USA) were used for qPCR on
7500 Real-Time PCR System. qPCR and reverse tran-
scription using TaqMan MicroRNA Reverse Transcrip-
tion Kit (Life Technologies, USA) was performed
following manufacturer’s recommendations. Results were
obtained by relative quantification using spike-in con-
trols cel-miR-39 in 49 newly diagnosed MM, 20 HD and
7 patients with renal cell carcinoma (RCC) in order to
distinguish miRNAs associated with MM. Analytical per-
formance of the study was assessed by intraplate and
interplate controls. Standard descriptive statistics were
applied in the analysis; median supplemented by inter-
quartile range for continuous variables. Statistical signifi-
cance of differences in continuous variables among
groups of patients was analyzed using nonparametric
Kruskal-Wallis or Mann–Whitney U test. Statistical ana-
lysis of data from validation phase of the study was per-
formed using IBM SPSS Statistics, v. 20. The study was
approved by the Ethics committee of the University
Hospital Brno. All patients were included into the study
only after they signed the informed consent form.
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BM: bone marrow; DN: diabetic nephropathy; HD: healthy donors;
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Table 3 Patients’ characteristics
HD RCC MM
No. of patients/donors 22 7 56
Gender: males-females 9-13 6-1 28-28
Age median (min-max)
[years]
57 (50–90) 61 (27–83) 69 (49–89)
ISS stage: I-II-III ND ND 16-12-19
D-S stage: I-II-III ND ND 3-7-40
D-S substage: A-B ND ND 39-11
Ig isotype: IgG-IgA-FLC ND ND 34-11-10
Light chains: kappa-lambda ND ND 40-15
Amount of M-Ig/FLC g/l
median (min-max)
ND ND 25,45 (0,17-65,4)
PCs infiltration in BM ND ND 13,1 (0,14-87,4)
No treatment ND ND 56 (100 %)
ND – not done, ISS stage – International Staging System stage, D-S stage – Durie-
Salmon stage, M-Ig – monoclonal immunoglobulin, FLC – Free Light Chains
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